What is INMB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for INMB?

P/E (TTM) is n/a and 52-week range is $1.09 to $2.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s INMB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for INMB?

The company profile lists revenue (TTM) near $50K, net income (TTM) near $-974M, EPS (TTM) near $-0.69 when available from the market-data feed. Figures are informational and may lag live markets.

Where is INmune Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boca Raton, Florida, US, 26.6M shares outstanding, ISIN US45782T1051 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

INmune Bio Inc

$INMB

Health Care · Biotechnology

IR Run Scenarios

$1.89

+3.28%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 21 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Employees

Website

www.inmunebio.com/

IPO

2019-02-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)